

News Release

Your Contact

Media Relations

esther.doeringer@emdgroup.com

Phone: +49 151 1454 7809

Investor Relations

investor.relations@emdgroup.com

Phone: +49 6151 72-3321

April 28, 2023

Annual General Meeting Approves all Agenda Items

Darmstadt, Germany, April 28, 2023 – Merck KGaA, Darmstadt, Germany, a leading science and technology company, held its 28th Annual General Meeting virtually today. All of the resolutions on the agenda were approved, including the proposed dividend of € 2.20 per share.

Shareholders also voted to authorize the Executive Board to decide on the appropriate format of the Annual General Meetings in 2024 and 2025, i.e. whether they will be held either virtually or in person. The Executive Board will take into account factors such as sustainability, costs, health and safety, the agenda items, and ensuring the broadest possible participation of shareholders.

At the Annual General Meeting today, around 93.8 million shares of the approximately 129.2 million shares issued were represented in the vote. This corresponds to 72.59% of the share capital. The details of the voting results and further information can be found at:

<https://www.emdgroup.com/en/investors/events-and-presentations/annual-general-meeting.html>.



News Release

All Merck KGaA, Darmstadt, Germany, press releases are distributed by e-mail at the same time they become available on the EMD Group website. In case you are a resident of the USA or Canada, please go to www.emdgroup.com/subscribe to register for your online, change your selection or discontinue this service.

About Merck KGaA, Darmstadt, Germany

Merck KGaA, Darmstadt, Germany, a leading science and technology company, operates across life science, healthcare and electronics. More than 64,000 employees work to make a positive difference to millions of people's lives every day by creating more joyful and sustainable ways to live. From providing products and services that accelerate drug development and manufacturing as well as discovering unique ways to treat the most challenging diseases to enabling the intelligence of devices – the company is everywhere. In 2022, Merck KGaA, Darmstadt, Germany, generated sales of € 22.2 billion in 66 countries.

The company holds the global rights to the name and trademark "Merck" internationally. The only exceptions are the United States and Canada, where the business sectors of Merck KGaA, Darmstadt, Germany, operate as MilliporeSigma in life science, EMD Serono in healthcare and EMD Electronics in electronics. Since its founding in 1668, scientific exploration and responsible entrepreneurship have been key to the company's technological and scientific advances. To this day, the founding family remains the majority owner of the publicly listed company.